296 related articles for article (PubMed ID: 27693274)
1. Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding.
Pignatelli P; Pastori D; Bartimoccia S; Menichelli D; Vicario T; Nocella C; Carnevale R; Violi F
Pharmacol Res; 2016 Nov; 113(Pt A):484-489. PubMed ID: 27693274
[TBL] [Abstract][Full Text] [Related]
2. Overview of the new oral anticoagulants: opportunities and challenges.
Yeh CH; Hogg K; Weitz JI
Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
[TBL] [Abstract][Full Text] [Related]
3. A review of oral anticoagulants in patients with atrial fibrillation.
Greenspon AJ
Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
[TBL] [Abstract][Full Text] [Related]
4. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
5. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
Stöllberger C; Finsterer J
Herz; 2015 Apr; 40 Suppl 2():140-5. PubMed ID: 25616425
[TBL] [Abstract][Full Text] [Related]
6. Nox2-mediated platelet activation by glycoprotein (GP) VI: Effect of rivaroxaban alone and in combination with aspirin.
Cammisotto V; Carnevale R; Nocella C; Stefanini L; Bartimoccia S; Coluccia A; Silvestri R; Pignatelli P; Pastori D; Violi F
Biochem Pharmacol; 2019 May; 163():111-118. PubMed ID: 30771281
[TBL] [Abstract][Full Text] [Related]
7. Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.
Eek AK; Øie E; Granas AG
Eur J Clin Pharmacol; 2018 Mar; 74(3):323-330. PubMed ID: 29149366
[TBL] [Abstract][Full Text] [Related]
8. New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint.
Rubboli A; Agewall S; Huber K; Lip GY
Int J Cardiol; 2015 Oct; 196():133-8. PubMed ID: 26093527
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the antithrombotic abilities of non-vitamin K antagonist oral anticoagulants using the Total Thrombus-formation Analysis System
Idemoto Y; Miura SI; Norimatsu K; Suematsu Y; Hitaka Y; Shiga Y; Morii J; Imaizumi S; Kuwano T; Iwata A; Zhang B; Ogawa M; Saku K
Heart Vessels; 2017 Mar; 32(3):309-316. PubMed ID: 27325226
[TBL] [Abstract][Full Text] [Related]
10. Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.
Saraf K; Morris PD; Garg P; Sheridan P; Storey R
Postgrad Med J; 2014 Sep; 90(1067):520-8. PubMed ID: 25085900
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulants: What is new and what is the standard?
Lesko LJ
Clin Pharmacol Ther; 2016 Aug; 100(2):126-8. PubMed ID: 27197625
[TBL] [Abstract][Full Text] [Related]
13. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoids impair platelet thromboxane biosynthesis in community-acquired pneumonia.
Cangemi R; Carnevale R; Nocella C; Calvieri C; Cammisotto V; Novo M; Castellani V; D'Amico A; Zerbinati C; Stefanini L; Violi F;
Pharmacol Res; 2018 May; 131():66-74. PubMed ID: 29577968
[TBL] [Abstract][Full Text] [Related]
15. Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.
Steppich B; Dobler F; Brendel LC; Hessling G; Braun SL; Steinsiek AL; Deisenhofer I; Hyseni A; Roest M; Ott I
J Thromb Thrombolysis; 2017 May; 43(4):490-497. PubMed ID: 28316004
[TBL] [Abstract][Full Text] [Related]
16. Mediterranean diet reduces thromboxane A2 production in atrial fibrillation patients.
Pignatelli P; Pastori D; Farcomeni A; Nocella C; Bartimoccia S; Vicario T; Bucci T; Carnevale R; Violi F
Clin Nutr; 2015 Oct; 34(5):899-903. PubMed ID: 25288566
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
18. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
19. A Comparison of the Rate of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin.
Cangemi DJ; Krill T; Weideman R; Cipher DJ; Spechler SJ; Feagins LA
Am J Gastroenterol; 2017 May; 112(5):734-739. PubMed ID: 28244496
[TBL] [Abstract][Full Text] [Related]
20. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
